Fiche publication
Date publication
janvier 2025
Journal
World journal of urology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
,
Dr CAZZATO Roberto-Luigi
Tous les auteurs :
Moinard-Butot F, Thouvenin J, Bigot P, Martinez-Chanza N, Gaillard V, Cazzato RL, Boissier R, Margue G, Boudier P, Maillet D, Gross-Goupil M, Bernhard JC, Barthélémy P
Lien Pubmed
Résumé
Surgery remains the cornerstone of localized renal cell carcinoma (RCC) care. Pembrolizumab has recently been recommended as a standard of care for RCC patients who are at high risk of recurrence. Data regarding the efficacy of ICIs either alone or in combination with ICIs or VEGF TKIs for VTT shrinkage are scarce.
Mots clés
Immunotherapy, Renal cell carcinoma, Tyrosine kinase inhibitor, Venous tumour thrombus
Référence
World J Urol. 2025 01 10;43(1):66
